Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704)

Kurokawa, Yukinori; Doki, Yuichiro; Kitabayashi, Ryo; Yoshikawa, Takaki; Nomura, Takashi; Tsuji, Kunihiro; Goto, Masahiro; Cho, Haruhiko; Hihara, Jun; Hiki, Naoki; Nunobe, Souya; Mizusawa, Junki; Boku, Narikazu; Terashima, Masanori

doi:https://doi.org/10.1007/s10120-023-01453-7

Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704)

Kurokawa, Yukinori; Doki, Yuichiro; Kitabayashi, Ryo et al.

Gastric Cancer, 2024, 27(2), 366-374

アクセス数:46件（2025-04-28 19:14 集計）

固定URL: https://hdl.handle.net/11094/94636

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
GastricCancer_27_2_366	pdf	なし	499 KB	64	2024.03.12

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704)
著者	NRID 1000010470197 1000010470197 researchmap permalink krkw krkw Scopus Author ID 7202562410 7202562410 著者名 Kurokawa, Yukinori
	NRID 1000020291445 1000020291445 researchmap permalink ydoki3251 ydoki3251 Scopus Author ID 7006390687 7006390687 著者名 Doki, Yuichiro
	著者名 Kitabayashi, Ryo
	NRID 1000030336573 1000030336573 著者名 Yoshikawa, Takaki
	著者名 Nomura, Takashi
	著者名 Tsuji, Kunihiro
	著者名 Goto, Masahiro
	著者名 Cho, Haruhiko
	NRID 1000010322744 1000010322744 著者名 Hihara, Jun
	NRID 1000030313026 1000030313026 著者名 Hiki, Naoki
	著者名 Nunobe, Souya
	著者名 Mizusawa, Junki
	NRID 1000050505948 1000050505948 著者名 Boku, Narikazu
	NRID 1000040197794 1000040197794 著者名 Terashima, Masanori
キーワード等	Bulky nodal involvement
	Neoadjuvant chemotherapy
	Para-aortic nodal metastases
	Perioperative chemotherapy
	Preoperative DOS
内容	The version of record of this article, first published in Gastric Cancer, is available online at Publisher’s website: https://doi.org/10.1007/s10120-023-01453-7.
抄録	Background: The prognosis for marginally resectable gastric cancer with extensive lymph node metastasis (ELM) remains unfavorable, even after R0 resection. To assess the safety and efficacy of preoperative docetaxel, oxaliplatin, and S-1 (DOS), we conducted a multicenter phase II trial. Methods: Eligibility criteria included histologically proven HER2-negative gastric adenocarcinoma with bulky nodal (bulky N) involvement around major branched arteries or para-aortic node (PAN) metastases. Patients received three cycles of docetaxel (40 mg/m², day 1), oxaliplatin (100 mg/m², day 1), and S-1 (80–120 mg/body, days 1–14), followed by gastrectomy with D2 plus PAN dissection. Subsequently, patients underwent postoperative chemotherapy with S-1 for 1 year. The primary endpoint was major (grade ≥ 2a) pathological response rate (pRR) according to the Japanese Classification of Gastric Carcinoma criteria. Results: Between October 2018 and March 2022, 47 patients (bulky N, 20; PAN, 17; both, 10) were enrolled in the trial. One patient was ineligible. Another declined any protocol treatments before initiation. Among the 45 eligible patients who initiated DOS chemotherapy, 44 (98%) completed 3 cycles and 42 (93%) underwent R0 resection. Major pRR and pathological complete response rates among the 46 eligible patients, including the patient who declined treatment, were 57% (26/46) and 24% (11/46), respectively. Common grade 3 or 4 toxicities were neutropenia (24%), anorexia (16%), febrile neutropenia (9%), and diarrhea (9%). No treatment-related deaths occurred. Conclusions: Preoperative chemotherapy with DOS yielded favorable pathological responses with an acceptable toxicity profile. This multimodal approach is highly promising for treating gastric cancer with ELM.
出版者	Springer
収録物名	Gastric Cancer
巻(号)	27(2)
ページ	366-374
刊行年月	2024-03-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/94636
PISSN	14363291
eISSN	14363305
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1007/s10120-023-01453-7
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Gastric Cancer. 2024, 27(2), p. 366-374
DC.title	Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704)
DC.creator	Kurokawa, Yukinori
	Doki, Yuichiro
	Kitabayashi, Ryo
	Yoshikawa, Takaki
	Nomura, Takashi
	Tsuji, Kunihiro
	Goto, Masahiro
	Cho, Haruhiko
	Hihara, Jun
	Hiki, Naoki
	Nunobe, Souya
	Mizusawa, Junki
	Boku, Narikazu
	Terashima, Masanori
DC.publisher	Springer
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-03-01
DC.identifier	https://doi.org/10.1007/s10120-023-01453-7
DC.subject	Bulky nodal involvement
	Neoadjuvant chemotherapy
	Para-aortic nodal metastases
	Perioperative chemotherapy
	Preoperative DOS
DC.description	The version of record of this article, first published in Gastric Cancer, is available online at Publisher’s website: https://doi.org/10.1007/s10120-023-01453-7.
DCTERMS.abstract	Background: The prognosis for marginally resectable gastric cancer with extensive lymph node metastasis (ELM) remains unfavorable, even after R0 resection. To assess the safety and efficacy of preoperative docetaxel, oxaliplatin, and S-1 (DOS), we conducted a multicenter phase II trial. Methods: Eligibility criteria included histologically proven HER2-negative gastric adenocarcinoma with bulky nodal (bulky N) involvement around major branched arteries or para-aortic node (PAN) metastases. Patients received three cycles of docetaxel (40 mg/m², day 1), oxaliplatin (100 mg/m², day 1), and S-1 (80–120 mg/body, days 1–14), followed by gastrectomy with D2 plus PAN dissection. Subsequently, patients underwent postoperative chemotherapy with S-1 for 1 year. The primary endpoint was major (grade ≥ 2a) pathological response rate (pRR) according to the Japanese Classification of Gastric Carcinoma criteria. Results: Between October 2018 and March 2022, 47 patients (bulky N, 20; PAN, 17; both, 10) were enrolled in the trial. One patient was ineligible. Another declined any protocol treatments before initiation. Among the 45 eligible patients who initiated DOS chemotherapy, 44 (98%) completed 3 cycles and 42 (93%) underwent R0 resection. Major pRR and pathological complete response rates among the 46 eligible patients, including the patient who declined treatment, were 57% (26/46) and 24% (11/46), respectively. Common grade 3 or 4 toxicities were neutropenia (24%), anorexia (16%), febrile neutropenia (9%), and diarrhea (9%). No treatment-related deaths occurred. Conclusions: Preoperative chemotherapy with DOS yielded favorable pathological responses with an acceptable toxicity profile. This multimodal approach is highly promising for treating gastric cancer with ELM.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	94636
citation_title	Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704)
citation_author	Kurokawa, Yukinori
	Doki, Yuichiro
	Kitabayashi, Ryo
	Yoshikawa, Takaki
	Nomura, Takashi
	Tsuji, Kunihiro
	Goto, Masahiro
	Cho, Haruhiko
	Hihara, Jun
	Hiki, Naoki
	Nunobe, Souya
	Mizusawa, Junki
	Boku, Narikazu
	Terashima, Masanori
citation_publisher	Springer
citation_language	英語
citation_date	2024-03-01
citation_journal_title	Gastric Cancer
citation_volume	27
citation_issue	2
citation_firstpage	366
citation_lastpage	374
citation_doi	https://doi.org/10.1007/s10120-023-01453-7
citation_public_url	https://hdl.handle.net/11094/94636

Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704)

閲覧可能ファイル

論文情報

論文詳細を表示